摘要
目的基于真实世界分析某院新型冠状病毒肺炎(COVID-19)确诊患者的临床用药,为临床合理用药提供建议。方法根据国家卫生健康委员会《新型冠状病毒肺炎诊疗方案(试行第七版)》推荐用药,对医院2020年1月30日至3月1日收治的19例COVID-19患者开展用药分析。结果确诊患者中,男女比例相当,年龄以30~50岁为主,多为亲属间传播,临床分型多为普通型;42.11%的患者入院前曾用药治疗,入院后多接受两联抗病毒药物治疗,其余对症治疗药物包括抗菌药物(47.37%)、呼吸系统药物(63.16%)、消化系统药物(10.53%)、保肝药物(36.84%)、抗焦虑药物(26.32%)、免疫调节药物(42.11%),中药注射剂和中药汤剂同时联用率为89.47%;47.37%的患者发生药品不良反应,主要原因为用药时间过长、联合用药不适宜、遴选药品不适宜等。结论19例COVID-19患者用药基本符合现行诊疗方案,但部分存在不合理用药现象,需规范临床用药,加强用药监护。
Objective To analyze the clinical medication of patients with the coronavirus disease 2019(COVID-19)in a hospital based on the real world,and provide suggestions for clinical rational use of drugs.Methods According to the drugs recommended in the Diagnosis and Treatment Plan for the COVID-19(Trial Version 7)released by the National Health Commission(NHC),the medication analysis was carried out on 19 patients with the COVID-19 admitted to the hospital from January 30th,2020 to March 1st,2020.Results Among the diagnosed patients,the proportion of male and female was equal,mainly in the population with 30-50 years old,most of them were spread among relatives,and their clinical classification mainly showed common type.42.11%of the patients had taken medication before admission,and most received two-suite antiviral drugs after admission,the other symptomatic drugs included antibiotics(47.37%),respiratory system drugs(63.16%),digestive system drugs(10.53%),l iver protection drugs(36.84%),anti-anxiety drugs(26.32%),immunomodulatory drugs(42.11%),t he combined use rate of traditional Chinese medicine(TCM)injection and TCM decoction was 89.47%.47.37%of the patients had adverse drug reactions,mainly due to the too long medication time,inappropriate combination of medication,inappropriate selection of drugs and so on.Conclusion The medication of 19 patients with COVID-19 basically conforms to the current diagnosis and treatment plan,but some patients have irrational medication.Therefore it is necessary to standardize clinical medication and strengthen medication monitoring.
作者
张家佳
蒋磊
芮贝贝
陈毅
刘锋
ZHANG Jiajia;JIANG Lei;RUI Beibei;CHEN Yi;LIU Feng(Anhui No.2 Provincial People's Hospital,Heifei,Anhui,China 230041)
出处
《中国药业》
CAS
2020年第7期54-57,共4页
China Pharmaceuticals
关键词
新型冠状病毒肺炎
用药分析
药品不良反应
合理用药
coronavirus disease 2019
medication analysis
adverse drug reactions
rational drug use